The IDH2 inhibitor drug, enasidenib has previously only been administered to elderly populations with acute myeloid leukemia. Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, discusses why this is the case, as well as the next steps for the drug. This includes further Phase II and III trials in all age groups to determine the efficiency of combination therapies. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
The next steps for the IDH2 inhibitor drug enasidenib
